GHULAM REHMAN MOHYUDDIN, MD
EDUCATION & TRAINING
- Fellow, Hematology-Oncology, University of Kansas Medical Center (2018-2021)
- Chief Resident, Internal Medicine, University of Kansas Medical Center (2017-2018)
- Resident, Internal Medicine, University of Kansas Medical Center (2014-2017)
- Medical School: Aga Khan University, Medical College, Karachi, Pakistan (2008-2013)
CURRENT POSITION Assistant Professor (Clinical), University of Utah, Division of Hematology/BMT (2021-Present)
BOARD CERTIFICATIONS
- American Board of Internal Medicine: Hematology and Medical Oncology (2021-Present)
- American Board of Internal Medicine: Internal Medicine (2017-Present)
SELECTED HONORS & AWARDS
- Health Tree Research Impact Award (2024 and 2025)
- University of Utah School of Medicine Fellowship Faculty Teaching Award (2023)
- Kansas Society of Clinical Oncology Outstanding Fellow Award (2020)
- Milton McGreevy Award, Best Graduating Resident (2017)
- Alpha Omega Alpha Honor Society (2016)
Principal Investigator of the following investigator led clinical trials:
- SPOTLIGHT Clinical Trial: Evaluates role of frequent whole body MRI’s as an alternative to pharmacological treatment for patients with high-risk smoldering myeloma
- ULTRA FRAIL-MM Clinical Trial: The first trial globally to exclusively enroll ultra-frail patients with myeloma
- IMPACT Trial: Assessing the role of budesonide in reducing diarrhea during transplant
PEER-REVIEWED PUBLICATIONS: (145+ total)
- Mohyuddin GR, et al. Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO Oncol Pract. 2025.
- Mohyuddin GR, et al. Overtreatment of multiple myeloma: de-escalation is urgent. Nat Rev Clin Oncol. 2024.
- Mohyuddin GR, et al. Quality of control groups in myeloma trials: systematic review. Lancet Haematol. 2021.
PROFESSIONAL MEMBERSHIPS American Society of Hematology | American Society of Clinical Oncology | American Society for Transplantation and Cellular Therapy | Alpha Omega Alpha Honor Medical Society
